Tandem Diabetes Completes $16 Million Follow-On Offering

Represented Tandem Diabetes Care (NASDAQ:TNDM) in connection with a follow-on public offering consisting of 4,630,000 shares of its common stock, Series A warrants to purchase 4,630,000 shares of its common stock and Series B warrants to purchase 4,630,000 shares of its common stock at a public offering price of $3.50 per share for gross proceeds of approximately $16.2 million. Tandem intends to use the proceeds from the offering for working capital and other general corporate purposes.

Tandem, based in San Diego, California, is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. Among other products, Tandem manufactures and sells the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.